Publicaciones en las que colabora con MARÍA LUISA CAÑADAS GARRE (28)

2021

  1. Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis

    Molecular Neurobiology, Vol. 58, Núm. 9, pp. 4716-4726

2020

  1. Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis

    Pathology Research and Practice, Vol. 216, Núm. 4

2019

  1. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

    Pharmacogenomics Journal, Vol. 19, Núm. 2, pp. 164-177

2018

  1. Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer

    Pathology Research and Practice, Vol. 214, Núm. 1, pp. 44-52

  2. Pharmacogenetic biomarkers of response in Crohn's disease

    Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 1-13

2017

  1. ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis

    Surgical Oncology, Vol. 26, Núm. 4, pp. 473-482

  2. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

    Mutation Research - Reviews in Mutation Research, Vol. 771, pp. 32-58

  3. Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer

    Pharmacogenetics and Genomics, Vol. 27, Núm. 12, pp. 438-444

  4. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer

    Surgical Oncology, Vol. 26, Núm. 3, pp. 278-285

2016

  1. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients

    Pharmacological Research, Vol. 108, pp. 111-118

  2. Gene polymorphisms as predictors of response to biological therapies in psoriasis patients

    Pharmacological Research, Vol. 113, pp. 71-80

  3. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis

    Pharmacological Research, Vol. 111, pp. 264-271

  4. Liquid biopsy in early stage lung cancer

    Translational Lung Cancer Research, Vol. 5, Núm. 5, pp. 517-524

  5. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients

    Pharmacological Research, Vol. 111, pp. 877-884

  6. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas

    Head and Neck, Vol. 38, Núm. 12, pp. 1772-1779

2015

  1. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer

    Pharmacogenomics, Vol. 16, Núm. 12, pp. 1411-1426

  2. Extrapolation of acenocoumarol pharmacogenetic algorithms

    Vascular Pharmacology, Vol. 74, pp. 151-157

  3. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer

    Pharmacological Research, Vol. 102, pp. 90-106

  4. MET: A new promising biomarker in non-small-cell lung carcinoma

    Pharmacogenomics, Vol. 16, Núm. 6, pp. 631-647

  5. Molecular biomarkers in colorectal carcinoma

    Pharmacogenomics, Vol. 16, Núm. 10, pp. 1189-1222